Augmented humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 after breakthrough infection in kidney transplant recipients who received 3 doses of coronavirus disease 2019 vaccine

This publication has 13 references indexed in Scilit:

• Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
  JAMA Internal Medicine, 2021
• The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
  Transplantation, 2021
• Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease
  JAMA Network Open, 2021
• Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients
  Transplantation, 2021
• Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
  Journal of Clinical Virology, 2021
• The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant
  Nephrology Dialysis Transplantation, 2021
• Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
  JAMA, 2021
• WHO International Standard for anti-SARS-CoV-2 immunoglobulin
  The Lancet, 2021
• The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression
  Transplantation, 2021
• Factors associated with COVID-19-related death using OpenSAFELY
  Nature, 2020